Rufus Collea is an Oncology physician affiliated with McKesson. OpenAlex indexes 16 publications with 315 citations (h-index 7); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
43 New Scotland Ave
Mail Code 7
Albany, NY 122083412
Telephone
518-262-6696Registry record last updated 19 Mar 2019.
Clinical trials
- Doxil & Carboplatin Plus HER2+ in Metastatic Breast Cancer
Sponsor: US Oncology Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20231 payment
- Seagen Inc.Program year20231 payment
- Gilead Sciences, Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
74.8%Other antiemetics68.8%Fosaprepitant100%Part B, office-administered≥20 patientsSerotonin-3 Receptor Antagonist6%Palonosetron hcl100%Part B, office-administered≥22 patientsMusculoskeletal
13.8%RANK Ligand Inhibitor13.8%Denosumab100%Part B, office-administered≥13 patientsSensory organs
6.4%Corticosteroid6.4%Dexamethasone sodium phosphate100%Part B, office-administered≥26 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Transitions in cancer care-moving from crisis intervention to care planning and management.
PubMed
2017 - Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole
Journal of Clinical Oncology
2016
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”